| Literature DB >> 36220305 |
Qingyong Zheng1,2, Jianguo Xu2,3, Ya Gao2,3,4, Ming Liu2,3,4, Luying Cheng1,2,5, Lu Xiong6, Jie Cheng1, Mengyuan Yuan1, Guoyuan OuYang1, Hengyi Huang1, Jiarui Wu7, Junhua Zhang8, Jinhui Tian9,3.
Abstract
INTRODUCTION: In recent years, the concept of living systematic review (LSR) has attracted the attention of many scholars and institutions. A growing number of studies have been conducted based on LSR methodology, but their focus direction is unclear. The objective of this study was to provide a comprehensive review of existing LSR-related studies and to analyse their whole picture and future trends with bibliometrics.Entities:
Keywords: health systems; review; systematic review
Mesh:
Year: 2022 PMID: 36220305 PMCID: PMC9558789 DOI: 10.1136/bmjgh-2022-009378
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Figure 1A timeline for the development of living systematic review. LNMA, living network meta-analysis; LSR, living systematic review.
The distribution of the top 10 authors and their institutions and countries
| Rank | Author | n (%) | Country | Institutional units |
| 1 | Skoetz N | 11 (5.2) | Germany | University of Cologne |
| 2 | Rada G | 11 (5.2) | Chile | Universidad Católica de Chile |
| 3 | Synnot A | 10 (4.7) | Australia | Monash University |
| 4 | Piechotta V | 10 (4.7) | Germany | University of Cologne |
| 5 | Ceravolo M G | 10 (4.7) | Italy | University of Ancona |
| 6 | Patrini M | 9 (4.2) | Italy | IRCCS Fondazione Don Gnocchi |
| 7 | Negrini F | 9 (4.2) | Italy | IRCCS Istituto Ortopedico Galeazzi |
| 8 | Monsef I | 9 (4.2) | Germany | University of Cologne |
| 9 | Lazzarini S G | 9 (4.2) | Italy | IRCCS Fondazione Don Gnocchi |
| 10 | Andrenelli E | 9 (4.2) | Italy | University of Ancona |
Figure 2Author collaboration network and cluster distribution.
Figure 3Current situation of national research publications and cooperation.
The top 10 journals in living systematic review-related field
| Rank | Journal | Region | Category | n (%) | Impact factor (2020) |
| 1 |
| England | Medicine, general and internal | 43 (20.2) | 9.266 |
| 2 |
| USA | Medicine, general and internal | 16 (7.5) | 25.391 |
| 3 |
| England | Medicine, general and internal | 15 (7.0) | 39.890 |
| 4 |
| Japan | Public, environmental and occupational health | 12 (5.6) | 6.437 |
| 5 |
| Italy | Rehabilitation | 9 (4.2) | 2.874 |
| 6 |
| Chile | Medicine, general and internal | 9 (4.2) | 2.522 |
| 7 |
| England | Medicine, general and internal | 7 (3.3) | 2.692 |
| 8 |
| USA | Neurosciences | 7 (3.3) | 5.269 |
| 9 |
| England | Medicine, general and internal | 7 (3.3) | 2.522 |
| 10 |
| USA | Oncology | 5 (2.3) | 44.544 |
Figure 4Clustering distribution of keywords co-occurrence hot spot network. LSR, living systematic review.
Top 10 cited living systematic review-related studies
| Rank | Title | First author | Year | Journal | TCs |
| 1 | Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal | Wynants L | 2020 |
| 888 |
| 2 | Antibody tests for identification of current and past infection with SARS-CoV-2 | Deeks J J | 2020 |
| 381 |
| 3 | Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis | Allotey J | 2020 |
| 338 |
| 4 | Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis | Buitrago-Garcia D | 2020 |
| 284 |
| 5 | Drug treatments for covid-19: living systematic review and network meta-analysis | Siemieniuk R A | 2020 |
| 233 |
| 6 | Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap | Elliott J H | 2014 |
| 225 |
| 7 | A living WHO guideline on drugs for covid-19 | Lamontagne F | 2020 |
| 198 |
| 8 | Living systematic review: 1. Introduction-the why, what, when, and how | Elliott J H | 2017 |
| 167 |
| 9 | Living systematic reviews: 2. Combining human and machine effort | Thomas J | 2017 |
| 124 |
| 10 | Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review | Hernandez A V | 2020 |
| 117 |
TCs, total citation times.
Update status of continuous living systematic review studies
| Rank | Title | n | Update frequency | Journal | Registration scheme |
| 1 | Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults | 9 | 8 |
| PROSPERO |
| 2 | Interventions for increasing fruit and vegetable consumption in children aged five years and under | 7 | 5 |
| Cochrane Database Syst Rev* |
| 3 | Rehabilitation and COVID-19: the Cochrane Rehabilitation 2020 rapid living systematic review | 7 | 6 |
| PROSPERO |
| 4 | Electronic cigarettes for smoking cessation | 6 | 3 |
| Cochrane Database Syst Rev* |
| 5 | Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review | 5 | 4 |
| Centre for Open Science |
| 6 | A living WHO guideline on drugs for covid-19 | 5 | 4 |
| – |
| 7 | Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review | 4 | 3 |
| – |
| 8 | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis | 4 | 2 |
| Cochrane Database Syst Rev* |
| 9 | Thoracic imaging tests for the diagnosis of COVID‐19 | 4 | 3 |
| Cochrane Database Syst Rev |
| 10 | Drug treatments for covid-19: living systematic review and network meta-analysis | 4 | 3 |
| – |
*Subsequent studies have shown changes in research plans that are inconsistent with the initial registration scheme.
Figure 5Strategic distribution of living systematic review related research concerns.